Allergan Tazoral Turned Down By FDA Cmte.: Off-Label Acne Use Is Concern
Executive Summary
Concerns about potential off-label use of Allergan's Tazoral as acne therapy figured heavily in an FDA advisory committee's recommendation against approving the retinoid drug for the treatment of moderate to severe psoriasis
You may also be interested in...
Accutane Scripts Would Be Limited To Approved Indication Under House Bill
Prescriptions for Roche's Accutane would be limited to the acne drug's approved indication under legislation introduced June 16 by Reps. Bart Stupak (D-Mich.) and Chris Smith (R-N.J.)
ALLERGAN TAZORAC PLAQUE PSORIASIS REDUCTION SUSTAINED "UP TO 12 WEEKS" AFTER TREATMENT; RETINOID GEL WILL BE LAUNCHED IN MID-JULY FOR PSORIASIS, ACNE
Allergan's once-daily Tazorac (tazarotene) maintains reductions in plaque psoriasis elevation, scaling and erythema severity 12 weeks after treatment, according to clinical study data included in Tazorac labeling.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011